Opal Wealth Advisors LLC Has $617,000 Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Opal Wealth Advisors LLC trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 17.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,186 shares of the medical research company’s stock after selling 250 shares during the period. Opal Wealth Advisors LLC’s holdings in Thermo Fisher Scientific were worth $617,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of TMO. Harbour Trust & Investment Management Co raised its stake in Thermo Fisher Scientific by 1.9% during the 4th quarter. Harbour Trust & Investment Management Co now owns 15,672 shares of the medical research company’s stock worth $8,153,000 after buying an additional 295 shares during the period. Angeles Wealth Management LLC raised its position in shares of Thermo Fisher Scientific by 0.6% during the fourth quarter. Angeles Wealth Management LLC now owns 3,943 shares of the medical research company’s stock worth $2,051,000 after purchasing an additional 22 shares during the period. Newbridge Financial Services Group Inc. bought a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $52,000. Kestra Private Wealth Services LLC lifted its stake in Thermo Fisher Scientific by 10.4% in the fourth quarter. Kestra Private Wealth Services LLC now owns 11,914 shares of the medical research company’s stock valued at $6,198,000 after buying an additional 1,118 shares in the last quarter. Finally, Howland Capital Management LLC increased its position in shares of Thermo Fisher Scientific by 2.7% during the fourth quarter. Howland Capital Management LLC now owns 79,771 shares of the medical research company’s stock worth $41,530,000 after acquiring an additional 2,098 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $571.44 on Monday. The company has a market capitalization of $218.58 billion, a price-to-earnings ratio of 34.57, a PEG ratio of 3.18 and a beta of 0.77. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. Thermo Fisher Scientific Inc. has a 52 week low of $493.30 and a 52 week high of $627.88. The company has a 50-day simple moving average of $547.34 and a 200 day simple moving average of $572.26.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific declared that its Board of Directors has approved a stock repurchase plan on Friday, November 15th that permits the company to buyback $4.00 billion in shares. This buyback authorization permits the medical research company to repurchase up to 2% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board of directors believes its shares are undervalued.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $175,677.00. Following the transaction, the executive vice president now owns 16,363 shares in the company, valued at $9,582,009.17. This trade represents a 1.80 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $530.26, for a total value of $5,302,600.00. Following the sale, the chief executive officer now directly owns 111,192 shares in the company, valued at approximately $58,960,669.92. This trade represents a 8.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 20,125 shares of company stock worth $11,231,699. Corporate insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Morgan Stanley upped their target price on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a research note on Friday, January 31st. Stifel Nicolaus decreased their price objective on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a report on Thursday, October 24th. Citigroup upped their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock a “neutral” rating in a research report on Friday, January 31st. Sanford C. Bernstein raised shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price objective on the stock in a research report on Friday, January 10th. Finally, Evercore ISI lowered their price target on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Four investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $658.00.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.